Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC JBI-589 | 2308504-22-3 | C29H28FN5O | 1 ML
Supplier: Medchemexpress LLC HY15345010MM/1ML
JBI-589 is a non-covalent, orally bioavailable, isoform-selective inhibitor of PAD4 (Protein Arginine Deiminase 4). It is suitable for use in cancer research, as it has been shown to reduce CXCR2 expression and block neutrophil chemotaxis, while also reducing primary tumor and metastases. This compound can enhance the anti-tumor effects of checkpoint inhibitors.
- Significantly downregulates CXCR2 expression on neutrophils
- Reduces CXCL1-induced migration
- Inhibits citrullination of histone H3 in induced mouse neutrophils
- Significantly inhibits primary tumor growth in mouse models
- Leads to a significant downregulation of CXCR2 receptor expression in Ly6G cells
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?